Affiliations: [a] Department of Radiology, The Affiliated Renmin Hospital of Jiangsu University, Zhenjiang, Jiangsu 212002, China | [b] State Key Laboratory of Bioelectronics, Jiangsu Key Laboratory of Biomaterials and Devices, School of Biological Science and Medical Engineering, Southeast University, Nanjing, Jiangsu 210096, China | [c] Medical college of Jiangsu University, Zhenjiang, Jiangsu 212013, China
Correspondence:
[*]
Corresponding author: Xiu-Hong Shan, Department of Radiology, The Affiliated Renmin Hospital of Jiangsu University, Zhenjiang, Jiangsu 212002, China. E-mail:13913433095@163.com
Abstract: BACKGROUND: Breast cancer is one of the most common type of female
cancer worldwide and represents 14% of cancer-related deaths in women.
Early detection is the most important factor for treatment and prognosis of
breast cancer. In most countries, the women are currently screened with
mammography only. Even though there has been considerable progress in the
detection, surgical therapy, hormonal and target therapy of breast cancer,
there are about ∼ 3500 000 women who die from breast cancer each year.
Therefore, there is an urgent need to explore the new techniques for early
detection of breast cancer. Magnetic resonance imaging (MRI) has the
potential to improve breast cancer detection at an early stage because of
its higher sensitivity. Glucose transporter (Glut) is a cellular
transmembrane receptor that plays key roles in cell glucose metabolism and
over-expressed in breast cancer cells. 2-deoxy-D-glucose having a similar
structure to D-glucose can specifically interact with Glut.
METHODS: In the present study, we constructed a
2-deoxy-D-glucose-functionalized superparamagnetic iron oxide (SPIO)
nanoparticles that coated with meso-2,3-dimercaptosuccinic acid (γ-Fe2O3@DMSA-DG NPs). The aim of this study is to evaluate the
efficacy of new constructed MRI contrast agent (γ-Fe2O3@DMSA-DG NPs) in detecting human breast cancers.
RESULTS: Our results showed that breast cancer cells MDA-MD-231,
MCF7 and ZR-75-1 had a high uptake rate of γ-Fe2O3@DMSA-DG
NPs than human breast fibroblast cell HUM-CELL-0056. There was a significant
difference of T2 relaxation times and signal intensity between breast
cancer cells and human breast fibroblast cells labeled with γ-Fe2O3@DMSA-DG NPs when MIR.
CONCLUSION: Our results
indicated that γ-Fe2O3@DMSA-DG NPs may be used as a new
MRI contrast agent for detection of breast cancer.
Keywords: Glucose transporter, breast cancer, SPIO, MRI
